NCT05376527View on ClinicalTrials.gov

Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 11, 2022

Primary Completion Date

February 27, 2025

Study Completion Date

February 27, 2025

Conditions
Oncolytic Virotherapy
Interventions
BIOLOGICAL

Double Recombinant Vaccinia Virus VV-GMCSF-Lact

"Intratumoral injections:~1\*107 PFU (calculated at minimal ED on mice); 2\*107 PFU; 4\*107 PFU; 6\*107 PFU; 8\*107 PFU; 10\*107 PFU;"

Trial Locations (1)

Unknown

N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg

All Listed Sponsors
collaborator

N.N. Petrov National Medical Research Center of Oncology

OTHER

lead

"Oncostar LLC"

INDUSTRY